title: Protease inhibitor treatment in HIV pregnant women. Is it safe for newborns?
authors.affiliation: Department of Obstetrics, Hospital Universitario La Fe, Valencia, Spain. ampagt@wanadoo.es
authors.forename: A
authors.initials: A
authors.lastname: García-Tejedor
authors.forename: A
authors.initials: A
authors.lastname: Perales
authors.forename: V
authors.initials: V
authors.lastname: Maiques
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D005260:Female; D005313:Fetal Death; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011256:Pregnancy Outcome; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D015215:Zidovudine / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine